Supreme Court Overturns Drug Calibration Patents, Creating Confusion In Biotech Realm

The court’s finding that Prometheus’ drug calibration test is unpatentable has left the biotech community reeling with uncertainty as to whether method of treatment claims, particularly those involving biomarkers, will be patent eligible.

More from United States

More from North America